Avid Radiopharmaceuticals, Inc. Sustainability Profile
Avid Radiopharmaceuticals, Inc., a leader in the radiopharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has made significant strides in the development of innovative imaging agents, particularly for neurodegenerative diseases. Avid is renowned for its flagship product, the FDA-approved radiotracer, which enhances the detection of amyloid plaques in the brain, a key indicator of Alzheimer’s disease. With a strong focus on advancing molecular imaging, Avid Radiopharmaceuticals has established itself as a pivotal player in the healthcare sector, contributing to improved diagnostic capabilities. The company’s commitment to research and development has led to notable achievements, positioning it as a trusted name among healthcare professionals and researchers alike. Through its cutting-edge products and services, Avid continues to shape the future of diagnostic imaging.
DitchCarbon Score
How does Avid Radiopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Avid Radiopharmaceuticals, Inc.'s score of 44 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Avid Radiopharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is a current subsidiary of Eli Lilly and Company, which influences its climate commitments and initiatives. Eli Lilly and Company, as the parent organisation, has established various climate initiatives that Avid Radiopharmaceuticals may align with. These include participation in the Carbon Disclosure Project (CDP) and commitments to renewable energy through the RE100 initiative, both of which are cascaded to Avid Radiopharmaceuticals at a level 1 relationship. While Avid Radiopharmaceuticals has not set its own specific reduction targets or disclosed its emissions, it benefits from the broader sustainability strategies of Eli Lilly, which may include significant reduction targets and climate pledges. As such, Avid Radiopharmaceuticals is positioned within a corporate framework that prioritises climate action, although specific metrics and targets for the subsidiary remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 502,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 200,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Avid Radiopharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Avid Radiopharmaceuticals, Inc.'s Location?
Avid Radiopharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Avid Radiopharmaceuticals, Inc.'s Scope 3 emissions, which increased by 62% last year and increased significantly since 2007, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 60% of Scope 3 emissions.
Top Scope 3 Categories
Avid Radiopharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Avid Radiopharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
